JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM)
- PMID: 31494831
- DOI: 10.1007/s12185-019-02730-x
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM)
Similar articles
-
[Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].Rinsho Ketsueki. 2021;62(8):1139-1148. doi: 10.11406/rinketsu.62.1139. Rinsho Ketsueki. 2021. PMID: 34497201 Review. Japanese.
-
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710. N Engl J Med. 2012. PMID: 22931316
-
Prognosis and treatment of Waldenström's macroglobulinemia.Transfus Apher Sci. 2010 Apr;42(2):193-7. doi: 10.1016/j.transci.2010.01.017. Epub 2010 Feb 8. Transfus Apher Sci. 2010. PMID: 20117052 Review.
-
XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features.Hematol Oncol. 2013 Jun;31 Suppl 1:76-80. doi: 10.1002/hon.2071. Hematol Oncol. 2013. PMID: 23775655 Review. No abstract available.
-
Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.Semin Oncol. 2003 Apr;30(2):201-5. doi: 10.1053/sonc.2003.50046. Semin Oncol. 2003. PMID: 12720136
Cited by
-
Impact of chromosomal aberrations detected by chromosome banding analysis in symptomatic Waldenström's macroglobulinemia.Ann Hematol. 2025 Jan;104(1):713-720. doi: 10.1007/s00277-024-06041-y. Epub 2024 Oct 16. Ann Hematol. 2025. PMID: 39412659 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources